This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Taking a More Target-Specific and Aggressive Approach to the Management of Chronic Urticaria

Taking a More Target-Specific and Aggressive Approach to the Management of Chronic Urticaria


Patient Case Study

Time to Complete

30 minutes


October 18, 2017


October 18, 2018
Add to Queue

Maximum Credits

0.50 / AMA PRA Category 1 CreditTM

Accredited Provider

Provided by Haymarket Medical Education

Commercial Supporter

Supported by an educational grant from Novartis Pharmaceuticals Corporation

Program Description

Despite a substantial body of evidence indicating that approximately half of patients with chronic idiopathic urticaria (CIU) are refractory to and obtain little or no benefit from even up-dosing of antihistamines, many clinicians do not move aggressively to next-phase treatment options or consider the mechanistic and target-specific properties and efficacy of guideline-recommended alternative agents. This Specialty House Call focuses on the importance of early use of validated assessment tools to gauge the degree of severity and the role of the full range of currently available agents—including corticosteroids, cyclosporine, and omalizumab—for patients with refractory CIU (also known as chronic spontaneous urticaria). The activity is notable for the inclusion of video segments of an actual CIU patient who shared her views on how CIU affected her quality of life, treatment strategies over time, and the status of her disease today.

Intended Audience

Allergists/immunologists, dermatologists, primary care physicians, and other healthcare providers who diagnose and manage patients with chronic urticaria

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Analyze the safety and efficacy of available and emerging immunobiologic therapies for refractory chronic urticaria
  • Utilize standardized tools to assess disease severity, response to treatment, and quality of life in patients who suffer from urticaria

Conflict Of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


Allen Kaplan, MD
Clinical Professor of Medicine
Medical University of South Carolina
Charleston, SC

Dr. Kaplan has no relevant financial relationships to disclose.

Luz Fonacier, MD, FACAAI, FAAAAI
Professor of Medicine
SUNY at Stony Brook
Stony Brook, NY
Head of Allergy
Program Director, Allergy & Immunology Fellowship Program
NYU Winthrop Hospital
Mineola, NY

Dr. Fonacier receives consulting fees from Church and Dwight, Co., Inc., and Regeneron Pharmaceuticals, and she performs contracted research as a principal investigator for Baxter Corp. and Genentech, Inc.

Accredited Provider Disclosure

Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education and Novartis Pharmaceuticals Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue